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The commensal fungus Candida albicans causes mucosal candidiasis in the rapidly expand-
ing number of immunocompromised patients. Mucosal candidiasis includes oropharyn-
geal, esophageal, gastrointestinal, and vaginal infections.Vulvovaginal candidiasis (VVC) and
antimycotic-refractory recurrent VVC is a frequent problem in healthy childbearing women.
Both these mucosal infections can affect the quality of life and finding new therapeutical
and preventive approaches is a challenge. A vaccine against candidal infections would be
a new important tool to prevent and/or cure mucosal candidiasis and would be of benefit
to many patients. Several Candida antigens have been proposed as vaccine candidates
including cell wall components and virulence factors. Here we discuss the recent progress
and problems associated with vaccination against mucosal candidiasis.
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INTRODUCTION
Candida albicans is a dimorphic fungus that colonizes different
areas of the body from the gastrointestinal tract to oral and
vaginal mucosa. It is usually a commensal microorganism but
in immunocompromised or otherwise debilitated hosts it can
cause disseminated and mucosal candidiasis. Systemic candidi-
asis is the fourth most common hospital-acquired infection in the
USA (Pfaller et al., 1998a,b). The associated mortality depends
on host conditions, and ranges between 30 and 50% (Pfaller
et al., 1998b; Kibbler et al., 2003). Invasive fungal infections are
common and severe in patients with hematologic malignancies,
leading to particularly high mortality. Somewhat different from
systemic infections, mucosal infections are common not only in
immunocompromised patients but also in apparently normal sub-
jects (Kirkpatrick, 2001). Their most common sites are the oral
cavity, and the gastrointestinal and vaginal tracts. Oral thrush is
one of the most frequent clinical forms of mucocutaneous can-
didiasis. It occurs at all ages with aggressive symptoms especially
in infants and elderly people (Lopez-Martinez, 2010).
Vulvovaginal candidiasis (VVC) is a common distressing infec-
tion that affects up to 75% of childbearing women worldwide at
least once in their life. Up to 7% of these women suffer from
frustrating recurrent infection (RVVC) defined as at least three or
four episodes of acute VVC in 1 year (Fidel, 2007; Sobel, 2007).
Two forms of RVVC have been described: idiopathic (Id) pri-
mary RVVC with unknown predisposing factors, and secondary
RVVC which occurs under predisposing conditions such as antibi-
otic treatment, oral contraceptive use, or diabetes mellitus (Fidel,
2004). These infections affect the quality of life, and require fre-
quent antimycotic treatment enhancing the risk of acquiring drug
resistance (Cassone, 2007).
Overall, the growing impact of fungal diseases has resulted in
renewed interest in new approaches for improving their control.
Among these new approaches, the generation of fungal vaccines
is recognized as a priority. A mucosal vaccine would improve the
quality of life of a long list of target populations of women suffering
from RVVC. The aim of this review is to discuss the recent progress
and problems associated with the development of a protective
mucosal vaccine against candidiasis.
INNATE IMMUNE RESPONSE AT MUCOSAL SURFACES
The immunopathology associated with mucosal candidiasis is still
not completely understood. The presence of C. albicans as a com-
mensal on the mucosal surface does not go unnoticed or tolerated
by the host – humoral and cellular factors of the innate and
acquired immune response play an important role in limiting the
growth of the fungus and neutralizing the activity of the virulence
factors (Cassone et al., 2007). Indeed the transition from asymp-
tomatic colonization to symptomatic infection occurs when the
local defenses are impaired and when the fungus becomes more
aggressive causing epithelial damage and inflammation through
the production of virulence factors. In addition, alteration of the
normal microbiota plays an important role.
The mucosal microbiota is acquired by colonization when pass-
ing through the birth canal, and soon after birth. The commensals
establish their residence in mucosal niches where they replicate
and play a crucial role in the development of the immune system.
The immune response to the microbiota at the mucosal surface
helps to maintain barriers to potentially harmful microorgan-
isms (Pirofski and Casadevall, 2012). C. albicans as a commensal
microorganism is part of normal microbiome in specific niches
such as the oral cavity, vagina, and gut in at least 50% of healthy
individuals. However it can cause pathology following alterations
of the local environment and/or impairment of the immune
response. To persist within the human host and cause disease at
the mucosal surfaces, C. albicans has acquired several distinct fac-
tors enabling these microorganisms to adhere to and invade host
cells.
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Epithelial cells (ECs) lining the mucosa play an essential role in
the defense against C. albicans. Indeed at the mucosal surface ECs
sense the presence of Candida and elaborate a number of mecha-
nisms to tolerate its presence and limit adherence, penetration, and
damage. It is clear that ECs recognize the fungus and are capable
of distinguishing its different forms of growth (Moyes et al., 2010),
however the relative role of pattern recognition receptors (PRRs)
in ECs is still largely unclear, despite the intensive research in PRR-
mediated interaction of C. albicans with myeloid cells (Netea et al.,
2006, 2008). The recognition of C. albicans by these cells has largely
been elucidated and the major PRRs and their putative ligands
derived from C. albicans have been extensively studied (Roeder
et al., 2004a,b; Netea et al., 2006). It is known that ECs express
PRRs: toll-like receptors (TLRs), dectin-1, and galectins (Backhed
and Hornef, 2003; Hornef and Bogdan, 2005; Weindl et al., 2007).
TLR2 and TLR5 are expressed at particularly high levels and these
receptors have been associated with biological functions of ECs
such as growth, survival, and repair (Rhee et al., 2005; Shaykhiev
et al., 2008).
CANDIDA RECOGNITION AT THE MUCOSAL SURFACE
Compelling evidence shows that C. albicans recognition by TLR4
on monocytes/macrophages results in release of proinflammatory
cytokines such as IL-1 and TNF-α (Netea et al., 2006) and also
the stimulation via TLR2 and FcγRII leads to TNF-α production
(Netea et al., 2008). TLR4, which is highly expressed on myeloid
cells and plays a critical role in driving immune response against
C. albicans (Netea et al., 2006), is poorly expressed in ECs at the
oral mucosal surface (Backhed and Hornef, 2003), and it seems
that TLR4 does not have a role in cytokine induction in response
to Candida (Li and Dongari-Bagtzoglou, 2009) and to other TLR4
ligands such as LPS (Naglik and Moyes, 2011).
At present, which fungal cell wall structures are recognized
in oral ECs is also unknown, however a recent study has estab-
lished that human oral ECs have a direct antifungal activity
demonstrating the important role of these cells in mucosal pro-
tection (Weindl et al., 2007). Indeed, the oral epithelium is able
to induce various defense effector molecules (Diamond et al.,
2008) and to orchestrate an immune response to activate immune
cells in the submucosal layers to clear the invading pathogens
(Cutler and Jotwani, 2006). It has also been reported that after
fungi recognition, infected ECs are activated and they produce
proinflammatory cytokines and chemokines including IL-8 which
induces neutrophil recruitment (Weindl et al., 2007; Moyes and
Naglik, 2011) into the mucosa surface. This could be considered
a mechanism of immune surveillance (Moyes and Naglik, 2011).
However, despite the beneficial role of these cells in protection
against systemic candidiasis, PMNs seem to exert no protective
role in vaginal candidiasis. Neutrophils are abundantly recovered
during vaginal candidiasis, but their presence was not associated
to reduction of fungal burden (Fidel et al., 1999). On the con-
trary, it has been hypothesized that ECs have high sensitivity to
Candida and secrete S100 alarmin resulting in a vigorous PMN
migration which results in an inflammatory response and symp-
toms of infection (Yano et al., 2010). In agreement with this, a live
challenge model in humans recently revealed that symptomatic
vaginitis is caused by an aggressive innate response (neutrophil
infiltrates and elevated fungal burden in the vaginal lumen); the
protection has been associated to a non-inflammatory innate
response (Fidel, 2007). Therefore the capacity of ECs to recruit
and activate neutrophils might be a double-edged sword, with
both favorable and unfavorable consequences depending on the
specific niche.
There is no doubt, therefore, that many aspects of EC interac-
tion withC. albicans, including the recognition of specific antigens
and regulation of the complicated network of regulatory activities
that characterize commensalism and infection in different niches,
remain to be studied.
T CELL RESPONSE IN MUCOSAL CANDIDIASIS
The role of T cells in mucosal candidiasis has only been partially
elucidated, and the attempt to integrate the defense response to
systemic and mucosal candidiasis remains inconclusive (Ashman
et al., 2011). There is a wealth of studies reporting that Th1-type
immunity is dependent on the presence of IL-12 in the milieu
(Trinchieri, 2003) and compelling evidence indicates that the Th1
response is protective against mucosal candidiasis. The benefi-
cial role of the Th1 response in oral candidiasis in particular has
been underlined (Schaller et al., 2004). In agreement with these
findings is the marked susceptibility of HIV-infected subjects to
oral candidiasis when CD4+ T cells are depleted, suggesting a
role for both Th1 and Th17 cell functional CD4 subsets. In addi-
tion, depletion of IL-12 resulted in acute susceptibility to oral
infection in a mouse experimental model (Farah et al., 2002;
Fidel, 2006; Zakikhany et al., 2007). In a report by Conti et al.
(2009) susceptibility to oropharyngeal candidiasis (OPC) in mice
with impaired Th1 and/or Th17 responses was compared. In this
study fungal infections of the tongue were less severe in mice
lacking IL-12p35 than in mice lacking IL-23p19, suggesting that
Th17 responses play a central role in control of infection. How-
ever, the fungal burden in both IL-12p35- and IL-23p19-deficient
mice was substantially higher than in controls, evidencing that
the absence of either Th1 or Th17 cells impaired the ability of
the mice to limit fungal growth (Pirofski and Casadevall, 2009).
As well as driving innate immunity and neutrophil responses,
Th17 cells have also been shown to drive antibody responses at
mucosal surfaces, in particular secretory IgA (Moyes and Naglik,
2011).
HUMORAL RESPONSE IN MUCOSAL CANDIDIASIS
For many years antibodies have been considered irrelevant in the
host defense against invasive candidiasis, but evidence for this
mode of protection has been mounting over the last two decades.
Indeed a number of antibodies or their engineered derivatives
directed against C. albicans cell wall compounds have been shown
to confer protection (Cutler et al., 2007, 2011; Cassone and Rap-
puoli, 2010; Xin and Cutler, 2011). The discovery of numerous
antigens on the fungal cell wall that elicit protective antibody
responses raises the possibility of vaccines designed with mul-
tiple antigens, and/or passive therapies that combine antibodies
with different specificities (Casadevall et al., 2004; Casadevall and
Pirofski, 2007).
Protective antibodies have been reported forC. albicans cell wall
polysaccharides, proteins, and peptides (De Bernardis et al., 1997;
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Matthews et al., 2003; Cutler, 2005; Yang et al., 2005; Xin et al.,
2008). As a prevention strategy, protection against disease may
be actively or passively acquired by vaccination and the admin-
istration of preformed monoclonal antibodies (Xin and Cutler,
2011).
In early studies protection against vaginal candidiasis was asso-
ciated with the presence of protective antibodies against Candida
constituents in the vaginal fluids and increased number of acti-
vated lymphocytes in the vaginal mucosa (De Bernardis et al.,
1997; de Bernardis et al., 2000). More recently the same group
demonstrated that vaginal B cells play an important role in pro-
tection against vaginal candidiasis suggesting that the contribution
of T cells is predominantly that of helping B cells in protective anti-
body production (De Bernardis et al., 2010). Recently, treatment
with synthetic peptides whose sequences are identical to fragments
from the constant region of different classes of antibodies has been
shown to provide protection against experimental vaginal can-
didiasis (Polonelli et al., 2012), and a protective effect in vaginal
candidiasis was also noticed after passive administration of anti-β-
glucan mAbs (Torosantucci et al., 2009). Unfortunately, the role of
Abs has rarely been investigated in other mucosal infections such
as oral candidiasis.
ANTI-CANDIDA VACCINES AND PROTECTION MECHANISMS
Recent papers support the idea that it may be possible to develop
an antifungal vaccine that grants protection against multiple fun-
gal pathogens (Cassone and Rappuoli, 2010; Stuehler et al., 2011;
Wuthrich et al., 2011). Some studies have focused on cell-mediated
immunity as the mechanism of protection (Spellberg et al., 2008),
which is in accordance with the literature (Xin et al., 2008), whereas
others (Cutler et al., 2007; Karwa and Wargo, 2009; Torosantucci
et al., 2009) have determined that antibodies specific to certain
Candida antigens are protective. Because of the variegate nature
of Candida virulence and participation of different host responses
in protection, it may well be possible that both humoral and cel-
lular responses play a role in vaccination, providing the necessary
collaboration to grant protection.
Several papers suggest that the induction of strong cellular
immunity plays a paramount role in protection against candidia-
sis. One approach for stimulating cellular immunity was priming
ex vivo dendritic cells (DCs) with fungal cells and re-administering
the loaded DCs to the host (Roy and Klein, 2012). Less recent
papers showed that DCs transfected with fungal RNA adoptively
transferred into otherwise susceptible recipients, did in fact con-
fer protection against C. albicans by inducing a protective Th1
response (Bozza et al., 2004; Perruccio et al., 2004). Recently a
novel antigenic peptide, derived from a cell wall-associated adhe-
sion and recognized by a major population of all Candida-specific
Th cells isolated from infected mice, was isolated and sequenced
from infected DCs. This peptide contributes to fungal patho-
genicity and it is conserved in many clinically important Candida
species such as C. dubliniensis and C. glabrata. Of note is the
fact that human Th cells also responded to stimulation with the
peptide. Furthermore when this peptide is used in combination
with an adjuvant inducing IL-17A secretion, it acts as an effi-
cient vaccine by protecting mice from fatal candidiasis (Bar et al.,
2012).
The fungal-specific antibody-mediated protection may occur
not only through classical immunological responses such as
phagocytosis and killing and complement activation, but also
through direct antibody actions on fungal cells, and even though
antibody protection is considered specific many fungal anti-
gens may be used for vaccination and to obtain therapeutic
immunoglobulins (Casadevall and Pirofski, 2012). The novel fully
synthetic β-(Man)3-Fba glycopeptide vaccine that represents two
epitopes of C. albicans cell surface has been shown to be pro-
tective in an experimental model of systemic candidiasis (Xin
et al., 2008). The protection was afforded with a strong antibody
response that was achieved by using a DC/Complete Freund Adju-
vant (CFA) combination (Xin et al., 2008). Indeed the antigen-
pulsed DC proved to be a powerful means to induce a potent
immune response that was not achieved by using small carbo-
hydrate and peptide antigens of C. albicans. More recently, by
coupling β-(Man)3-Fba glycopeptide to tetanus toxoid to render
this vaccine entirely compatible with human use, a high degree
of antibody-mediated protection was observed (Xin et al., 2012).
These vaccine formulations also proved protective in mucosal
models of infection (Xin et al., 2012). Another important effort
to induce protection against C. albicans was made by Li et al.
(2011) who showed that treatment with recombinant enolase, an
important glycolytic enzyme located on the cell wall of C. albicans,
conferred a protective effect against systemic challenge evaluated
by fungal burdens in target organs, titers of specific antibodies to
enolase, and levels of Th1/2 cytokines in serum.
VACCINE CANDIDATES FOR MUCOSAL CANDIDIASIS
Strategies to elaborate a vaccine for mucosal candidiasis should
take into account what type of immune response is protective
under natural conditions, but should not necessarily be limited
to mimicking the natural history of mucosal infection and pro-
tection. Hence, several studies have focused on different strategies
to induce protection against vaginal candidiasis. In particular, it
has been reported that vaccination with the recombinant N ter-
minus of the candidal adhesin rAls3p-N protects mice against
disseminated and oropharyngeal and vaginal candidiasis by a cell-
mediated immune response (Th1/Th17). Antibodies have also
been generated but their titers did not correlate with protec-
tion. The rAls3p-N vaccine is a promising new vaccine candidate
for further exploration to prevent systemic and mucosal candi-
dal infections (Spellberg et al., 2006). It has recently completed
a Phase 1 clinical trial and proved to be safe and immunogenic.
In particular, this research group reported that vaginal and sys-
temic protective responses could be achieved by vaccination with
rAls3-N which stimulates Th1/Th17 lymphocytes to produce high
levels of IFN-γ and IL-17A, as well as the chemokines KC and
MIP-1. These cytokines enhance the capacity of phagocytes to kill
the pathogen. This vaccine protects immunocompetent mice from
both vaginal candidiasis and lethal disseminated candidiasis and it
also significantly reduces oral fungal burden in the corticosteroid-
treated mouse model of OPC. Human trials with the rAls3-N
vaccine are in final preparation (Liu and Filler, 2011). An addi-
tional approach to achieve protection against mucosal infection
was immunization with C. albicans dsDNA which induces host
resistance in newborn mice against gastrointestinal C. albicans
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infection. The protective properties of dsDNA are related to an
increased number of CD4+ T cells secreting IFN-γ (Remichkova
et al., 2009).
One attempt to develop a mucosal vaccination was by using an
aspartyl proteinase (Sap2), a very well known enzyme belonging to
a family of virulence factors of C. albicans (Naglik et al., 2003). Pre-
vious clinical and experimental work strongly suggested that Sap2
and possibly other Saps were involved in vaginal infection (Cas-
sone et al., 1987; De Bernardis et al., 1990). Mice immunized with
Sap2 showed significantly reduced fungal burdens both orally and
vaginally, and rats receiving intravaginal administration of anti-
Sap2 antibodies were protected by an intravaginal challenge by
C. albicans. These studies demonstrated that Sap2 is an immuno-
genic antigen capable of inducing protective responses against C.
albicans colonization and infection, and tentatively supports its
targeting as a potential vaccine candidate (Rahman et al., 2007).
The role of Sap2 in inducing protection against mucosal candidi-
asis has more recently been underscored by Sandini et al. (2011).
These authors generated a recombinant truncated Sap2 protein
(rSap2t) and reported that intravaginal immunization with this
antigen and cholera toxin as an adjuvant protected from the chal-
lenge of a highly vaginopathic strain of C. albicans. Protection was
possibly due to the elicitation of specific antibodies IgM and IgG
anti-rSap2t. More recently rSap2t was incorporated into influenza
virosomes, an adjuvant/carrier formulation already used in other
human vaccines, which avoids the necessity for a toxin adjuvant.
This formulation generated a potent serum antibody response in
the mouse and rat following intramuscular immunization. In a
rat model of candidal vaginitis the intravaginal or intramuscu-
lar administration of rSap2t induced production of anti-Sap2 IgG
and IgA in the vaginal fluid, which conferred a consistent degree
of protection against vaginal C. albicans infection (De Bernardis
et al., 2012).
In another study, murine mAb (KT4, IgG1) was used, neu-
tralizing in vitro the anti-Candida activity as an Id vaccine to
elicit Abs. An effective protection that correlated with a significant
decrease in vaginal Candida CFU was obtained in Id-vaccinated
animals compared with controls. The protection was associated
with rising vaginal titers of anti-idiotypic Abs (IdAb), prevalently
of the IgA isotype, that were able to passively transfer the protec-
tive state to non-immunized animals (Polonelli et al., 1994). Since
the receptor of the killer toxin recognized by the mAbKT4 is a
beta-glucan molecule, it is possible that the protection conferred
by the Id vaccine somewhat parallels the protection conferred by
the β-glucan-conjugate vaccine (see below).
In a further work, immunization was performed with C. albi-
cans heat shock protein 90 kDa (hsp90-CA). Intradermal priming
with recombinant hsp90-CA protein, followed by an intranasal or
intradermal booster with recombinant hsp90-CA protein, induced
significant increases of specific IgG and IgA antibodies in both
serum and vaginal fluid. The specific IgG isotype increased after
vaginal Candida infection, suggesting that Candida has the ability
to induce a local hsp90-specific antibody (IgG) response during
VVC (Raska et al., 2008).
A vaccine composed of β-glucan has been considered a can-
didate against Candida and other fungi. A non-fungal source
of β-glucan, laminarin, has been used in these studies. Because
polysaccharides are poor immunogens, laminarin was conjugated
with the diphtheria toxoid CRM197. This novel glyco-conjugate
vaccine administered with human-compatible adjuvant resulted
immunogenic and protective as a prophylactic against experimen-
tal systemic and mucosal infections by C. albicans (Torosantucci
et al., 2005). The protection has been ascribed to the production of
antibodies to β-(1,3)-glucan (Bromuro et al., 2010). The protec-
tive capacity of this β-glucan-conjugate vaccine formulated with
the human-compatible MF59 adjuvant was assessed in a murine
model of vaginal candidiasis exploiting an in vivo imaging tech-
nique to monitor the infection. The vaccine conferred significant
protection, which was associated to anti-β-glucan IgG antibod-
ies in the serum and in the vagina. The efficacy of the antibodies
was demonstrated by the passive transfer of the immune vaginal
fluid or anti-β-glucan monoclonal antibodies to naïve mice before
infection (Pietrella et al., 2010). The main vaccine candidates are
reported in Table 1.
CONCLUSION
Despite several promising approaches, the achievement of a vac-
cine against mucosal infections in humans still faces a number of
problems and challenges. The major challenge remains the diffi-
culties in translating results from rodents to humans, as rodent
models can represent at best only part of the variegate patterns
of vaginal Candida infections in women (Sobel, 2007). In fact
most of the data indicating that protection against vaginal infec-
tion has been obtained in the rat model, and is not considered
by some to be fully representative of the human infection (Fidel
and Cutler, 2011). In addition, very few vaccination studies have
addressed oral and other types of mucosal candidiasis. Another
issue is that vaccine-induced protection must occur in specific
niches where C. albicans is tolerated as a commensal organism,
and it cannot be excluded that affecting fungus colonization by
a vaccine could induce some harm in the host by affecting the
mucosal microbiome. Other issues concern the search for new
vaccine immunogens and adjuvants by existing advanced tech-
nologies. It should be taken into account that the most studied
vaccines, particularly those in clinical trials (the virosomal Sap2
and the Als3 peptide) have been generated by classical “empiric”
approaches, including clinical impressions. Now, a large variety of
covalently attached proteins has been found in fungal walls and
these proteins can rapidly change their expression in response to
different environmental conditions. The knowledge of the specific
proteome of the fungus in the host is fundamental for the iden-
tification of new vaccine candidates (Klis et al., 2011). Not only
proteomics but also complementary post-genomic tools such as
transcriptomics and metabolomics in a systems biology context
will be useful tools to study pathogen-host interaction, to identify
the protective response during infection and the immune response
after vaccination. In a recent study, through an integrated analy-
sis of genome-wide transcriptome, Lindqvist et al. determined
which signature pathways, processes, and networks are shared by
or are exclusive to two classes of experimental vaginal adjuvants,
the TLR-9 agonist CpG-ODN and alpha-galactosylceramide in
the mouse vagina. These molecular signatures could be used to
develop potent mucosal adjuvants that can be used in the female
genital tract of a mammal (Lindqvist et al., 2011).
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Table 1 |Vaccine candidates for protection against candidiasis.
Components Reference Protective immunity Protection
1,3-β-glucan Torosantucci et al. (2009), Cassone et al.
(2010), Bromuro et al. (2010)
Abs Systemic
rHyr1p-N Luo et al. (2011) Abs Systemic
Mannoproteins De Bernardis et al. (2010) B cells Vaginal
Pietrella et al. (2002) Th1 Systemic
β-1,2-mannotriose-Fba Xin et al. (2012) Abs Systemic
Heat shock proteins 90 Raska et al. (2008) Abs Systemic and vaginal
C. albicans surface protein, Als3p
(Agglutinin-Like Sequence 3) rAls3-N
Spellberg et al. (2008) Th1–Th17 Systemic
Baquir et al. (2010), Liu and Filler (2011) Abs Vaginal, systemic,
and oral
Phosphoglycerate kinase Calcedo et al. (2012) Abs Oral
Secreted aspartic proteases 2 De Bernardis et al. (2012), Cassone and
Casadevall (2012)
Abs Mucosal and vaginal
Yeast derived-β glucan particles (GPs) Huang et al. (2010) Th1, Th17, Abs NT
DCs transfected with fungal RNA Bozza et al. (2004), Perruccio et al. (2004) T cell response Th1 Systemic
Nanoparticle-mediated target DCs Roy and Klein (2012) T cell response NT
Liposome-mannan (L-mann) Han et al. (2000) Abs to β-1,2-mannotriose Systemic and vaginal
Daucosterol Lim et al. (2007) Th1 Systemic
Enolase Li et al. (2011) Abs Th1 Systemic
Glycopeptide or a peptide synthetic
vaccine, (Candida albicans cell wall-derived)
Xin et al. (2012) Abs Systemic
Fba, (peptide derived from fructose
bisphosphate aldolase which has cytosolic
and cell wall distributions in the fungus)
Cutler et al. (2011) Abs Systemic
C. albicans dsDNA Remichkova et al. (2009) T cells (Th1) Gastrointestinal
NT, not tested.
Knowledge of the host mechanisms involved in candidia-
sis protection, and understanding of the fungal virulence fac-
tors, will allow the development of a novel topical mucosal
vaccine.
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